TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06228053: Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

Sponsor: Syntrix Biosystems, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 53 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,524,600

Rescue Site Savings

+$1,016,400

Unlock Full NCT06228053 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06228053 Rescue Dossier →